Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 1 Dose-Escalation and Expansion Study of BGB-16673 in Patients With B-Cell Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05006716
Recruitment Status : Recruiting
First Posted : August 16, 2021
Last Update Posted : May 12, 2022
Sponsor:
Information provided by (Responsible Party):
BeiGene

Brief Summary:
Study consists of two parts to explore BGB-16673 recommended dosing, a part 1 monotherapy dose finding and a part 2 (cohort expansion in two cohorts)

Condition or disease Intervention/treatment Phase
B-cell Malignancy Marginal Zone Lymphoma Follicular Lymphoma Non-hodgkin Lymphoma Waldenström Macroglobulinemia Drug: BGB-16673 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 76 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies
Actual Study Start Date : September 13, 2021
Estimated Primary Completion Date : May 30, 2024
Estimated Study Completion Date : November 30, 2025


Arm Intervention/treatment
Experimental: Part 1 Monotherapy Dose Finding
BGB-16673
Drug: BGB-16673
BGB-16673 doses are to be administered as a once daily regimen

Experimental: Part 2 Expansion Cohorts
BGB-11673 for two expansion cohorts
Drug: BGB-16673
BGB-16673 doses are to be administered as a once daily regimen




Primary Outcome Measures :
  1. Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) with adverse events leading to discontinuation, and AEs graded according NCI-CTCAE V5. [ Time Frame: approximately 3 years ]

    also may be assessed using the 2018 iwCLL Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of CLLA.

    TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pretreatment) on or after the date of the first dose of the study drug and up to 30 days after the last dose of study treatment or the initiation of a new anticancer therapy, whichever is earlier


  2. Recommended Phase 2 Dose (RP2D) of Orally Administered BGB-16673 [ Time Frame: approximately 3 years ]
    The RP2D is the maximum tolerated dose (MTD) or less. An RP2D less than the MTD may be chosen if aspects of tolerability or efficacy not encompassed by the MTD determination suggest utilizing a lower dose


Secondary Outcome Measures :
  1. Single Dose Maximum observed plasma concentration (Cmax) of BGB-16673 [ Time Frame: Day 1 pre-dose and 2, 4, 6,8,24, 48 and 72 hours post-dose (approximately 2 years) ]
    Collected for both Part 1 and Part 2

  2. Single Dose Minimum observed plasma concentration (Cmin) of BGB-16673 [ Time Frame: Day 1 pre-dose and 2, 4, 6,8,24, 48 and 72 hours post-dose (approximately 2 years) ]
    Collected for both Part 1 and Part 2

  3. Single Dose Time to reach Cmax (tmax) of BGB-16673 [ Time Frame: Day 1 pre-dose and 2, 4, 6,8,24, 48 and 72 hours post-dose (approximately 2 years) ]
    Collected for both Part 1 and Part 2

  4. Single Dose Time to reach half of Cmax (T1/2) of BGB-16673 [ Time Frame: Day 1 pre-dose and 2, 4, 6,8,24, 48 and 72 hours post-dose (approximately 2 years) ]
    Collected for both Part 1 and Part 2

  5. Single Dose Area under the plasma concentration-time curve (AUC) of BGB-16673 [ Time Frame: Day 1 pre-dose and 2, 4, 6,8,24, 48 and 72 hours post-dose (approximately 2 years) ]
    Collected for both Part 1 and Part 2

  6. Single Dose apparent total clearance of drug from plasma after oral administration (CL/F) of BGB-16673 [ Time Frame: Day 1 pre-dose and 2, 4, 6,8,24, 48 and 72 hours post-dose (approximately 2 years) ]
    Collected for both Part 1 and Part 2

  7. Single Dose apparent volume of distribution (Vz/F) of BGB-16673 [ Time Frame: Day 1 pre-dose and 2, 4, 6,8,24, 48 and 72 hours post-dose (approximately 2 years) ]
    Collected for both Part 1 and Part 2

  8. Single Dose accumulation ratios of BGB-16673 [ Time Frame: Day 1 pre-dose and 2, 4, 6,8,24, 48 and 72 hours post-dose (approximately 2 years) ]
    Collected for both Part 1 and Part 2

  9. Steady State Maximum observed plasma concentration (Cmax) of BGB-16673 [ Time Frame: Day 1 pre-dose and 2, 4, 6,8,24, 48 and 72 hours post-dose (approximately 2 years) ]
    Collected for both Part 1 and Part 2

  10. Steady State minimum observed plasma concentration (Cmin) of BGB-16673 [ Time Frame: Day 1 pre-dose and 2, 4, 6,8,24, 48 and 72 hours post-dose (approximately 2 years) ]
    Collected for both Part 1 and Part 2

  11. Steady State Time to reach Cmax (tmax) of BGB-16673 [ Time Frame: Day 1 pre-dose and 2, 4, 6,8,24, 48 and 72 hours post-dose (approximately 2 years) ]
    Collected for both Part 1 and Part 2

  12. Steady State Time to reach half of Cmax (T1/2) of BGB-16673 [ Time Frame: Day 1 pre-dose and 2, 4, 6,8,24, 48 and 72 hours post-dose (approximately 2 years) ]
    Collected for both Part 1 and Part 2

  13. Steady State Area under the plasma concentration-time curve (AUC) of BGB-16673 [ Time Frame: Day 1 pre-dose and 2, 4, 6,8,24, 48 and 72 hours post-dose (approximately 2 years) ]
    Collected for both Part 1 and Part 2

  14. Steady State apparent total clearance of drug from plasma after oral administration (CL/F) of BGB-16673 [ Time Frame: Day 1 pre-dose and 2, 4, 6,8,24, 48 and 72 hours post-dose (approximately 2 years) ]
    Collected for both Part 1 and Part 2

  15. Steady State apparent volume of distribution (Vz/F) of BGB-16673 [ Time Frame: Day 1 pre-dose and 2, 4, 6,8,24, 48 and 72 hours post-dose (approximately 2 years) ]
    Collected for both Part 1 and Part 2

  16. BTK protein degradation in peripheral blood upon BGB-16673 monotherapy [ Time Frame: Day 1 pre-dose and 8 hours post-dose (approximately 2 years) ]
  17. Number of Participants with overall response rate (ORR) [ Time Frame: approximately 3 years ]
    Best overall response is defined as the best response recorded from the first dose of the study drug until data cut or the initiation of a new anticancer treatment

  18. Number of WM Participants with major response rate (MRR) [ Time Frame: approximately 3 years ]
    MRR is defined as the proportion of patients whose best overall response (BOR) is partial response (PR) or better (PR, very good partial response [VGPR], or complete response (CR)).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Provision of signed and dated written informed consent prior to any study-specific procedures, sampling, or data collection
  2. Age ≥ 18 years
  3. Confirmed diagnosis (per World Health Organization [WHO] guidelines, unless otherwise noted) of one of the following: MZL, FL, MCL, CLL/SLL, or WM.
  4. Patients who have previously received a covalently-binding BTK inhibitor in any line of therapy must have received treatment with the BTK inhibitor for ≥ 8 weeks.
  5. For dose-finding and dose-expansion, patients who had previously received a covalently-binding BTK inhibitor as monotherapy or in combination with other anticancer agents are eligible for the study if they meet any of the following criteria: discontinued the previous BTK inhibitor due to disease progression, experienced disease progression after completing treatment with a BTK inhibitor or discontinued the BTK inhibitor due to toxicity or intolerance.
  6. Measurable disease by radiographic assessment or serum IgM level (WM only)
  7. ECOG Performance Status of 0 to 2
  8. Patients enrolling in the dose finding phase of the study may be previously treated with a BTKi or may be naïve to BTKi therapy; patients with CLL/SLL or MCL enrolling in the expansion cohorts must have been treated with a BTKi in a prior line of therapy.

Exclusion Criteria:

  1. Prior malignancy (other than the disease under study) within the past 2 years, except for curatively treated basal or squamous skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score ≤ 6 prostate cancer
  2. Requires ongoing systemic treatment for any other malignancy
  3. Requires ongoing systemic (defined as ≥ 10 mg/day of prednisone or equivalent) corticosteroid treatment.
  4. Current or history of central nervous system involvement including the brain, spinal cord, leptomeninges, and cerebrospinal fluid (as documented by imaging, cytology, or biopsy) by B-cell malignancy, regardless of whether patient had received treatment for central nervous system disease
  5. Known active plasma cell neoplasm, prolymphocytic leukemia, , T-cell lymphoma, Burkitt lymphoma, acquired immunodeficiency syndrome (AIDS)-related B-cell lymphoma, Castleman disease, post-transplant lymphoproliferative disorders, hairy cell leukemia, or

Note: Other protocol defined Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05006716


Contacts
Layout table for location contacts
Contact: BeiGene 1.877.828.5568 clinicaltrials@beigene.com
Contact: Study Director, MD

Locations
Layout table for location information
United States, Kentucky
Norton Cancer Institute, St. Matthews Campus Recruiting
Louisville, Kentucky, United States, 40207
United States, Texas
The University of Texas, MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Australia, New South Wales
Concord Repatriation General Hospital Recruiting
Concord, New South Wales, Australia, 2139
Australia, Victoria
Peter MacCallum Cancer Institute Recruiting
Melbourne, Victoria, Australia, 3000
The Alfred Hospital Recruiting
Melbourne, Victoria, Australia, 3004
Australia, Western Australia
Perth Blood Institute Recruiting
West Perth, Western Australia, Australia, 6005
Australia
Linear Clinical Research Recruiting
Nedlands, Australia, 6009
Sponsors and Collaborators
BeiGene
Layout table for additonal information
Responsible Party: BeiGene
ClinicalTrials.gov Identifier: NCT05006716    
Other Study ID Numbers: BGB-16673-101
First Posted: August 16, 2021    Key Record Dates
Last Update Posted: May 12, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Neoplasms
Lymphoma, B-Cell, Marginal Zone
Waldenstrom Macroglobulinemia
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Neoplasms, Plasma Cell
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders